health

Dr. Laurie Santos teaches a psychology course at Yale called The Science of Well-Being. It’s the most popular class in the university’s 300-year history. She also has a podcast called The Happiness Lab where she shares her findings on what people can do to live a happier and more fulfilling life.

Nature Medicine, Published online: 16 September 2024; doi:10.1038/s41591-024-03249-3

In the phase 2 adaptive BELLINI trial, patients with early-stage triple-negative breast cancer received neoadjuvant nivolumab with or without ipilimumab, showing immune activation, clearance of circulating tumor DNA and promising clinical response rates, especially in patients preselected based on high levels of tumor-infiltrating lymphocytes.

Nature Medicine, Published online: 16 September 2024; doi:10.1038/s41591-024-03254-6

In a large cohort with a 23-month median follow-up of the CIRCULATE-Japan GALAXY observational study, ctDNA-based detection of molecular residual disease was predictive of survival outcomes and benefit of adjuvant chemotherapy in patients with resectable colorectal cancer.

Nature Medicine, Published online: 16 September 2024; doi:10.1038/s41591-024-03294-y

Author Correction: Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations

Nature Medicine, Published online: 16 September 2024; doi:10.1038/s41591-024-03293-z

Author Correction: Not all AI health tools with regulatory authorization are clinically validated

Nature Medicine, Published online: 15 September 2024; doi:10.1038/s41591-024-03250-w

In the phase 2 NICHE-3 trial, patients with locally advanced mismatch repair-deficient colon cancer who were treated with neoadjuvant anti-PD1 and anti-LAG3 agents showed high rates of pathological responses, requiring validation in larger trials.

Nature Medicine, Published online: 14 September 2024; doi:10.1038/s41591-024-03267-1

In the I-SPY2.2 trial, patients with high-risk stage 2/3 breast cancer received neoadjuvant datopotamab–deruxtecan plus durvalumab, followed by sequential chemotherapy with or without targeted therapy, with the option of early surgical resection after each block of therapy, showing that de-escalation of therapy is possible for several patient subgroups without compromising outcome and avoiding toxicity of standard chemotherapy.

Nature Medicine, Published online: 14 September 2024; doi:10.1038/s41591-024-03266-2

In the I-SPY2.2 trial, patients with high-risk stage 2/3 breast cancer received neoadjuvant datopotamab–deruxtecan, followed by sequential chemotherapy with or without targeted therapy, with the option of early surgical resection after each block of therapy. In a subgroup of patients, the sequential treatment strategy was superior to standard of care.

Nature Medicine, Published online: 13 September 2024; doi:10.1038/s41591-024-03241-x

Post-approval evidence generation is essential for high-quality clinical care and should be a shared priority for clinicians, health systems, payors, and the medical products industry, as well as the FDA and federal agencies.

Nature Medicine, Published online: 13 September 2024; doi:10.1038/s41591-024-03217-x

A novel application of antisense oligonucleotide (ASO) technology, developed to treat a single patient, adds to the growing number of ‘personalized’ therapies for rare diseases; but pathways to implementation and access are urgently needed.